Giora Sharf Discusses Ways to Represent the CML Patient Voice

There are many ways patients with chronic myelogenous leukemia can ensure they are active participants in their own treatment, according to Giora Sharf, co-founder of the CML Advocates Network.

Becoming active participants in their own care by understanding treatments and becoming a full partner with their physicians is not the extent to which patients with chronic myelogenous leukemia (CML) can make sure their voices are heard, Giora Sharf, co-founder of the CML Advocates Network, said at the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, California.

In addition to empowering patients by educating them with materials like patient-friendly guidelines to CML treatment, his network is partnered with companies and researchers so the patient voice can be heard during the research and development process and they can be represented throughout the entire process.